<DOC>
	<DOCNO>NCT01433302</DOCNO>
	<brief_summary>The goal clinical research study measure amount inflammatory protein inside body lymphatico-venular bypass surgery . This help doctor learn anti-fibrotic anti-inflammatory drugs/treatments give surgery improve well surgery work .</brief_summary>
	<brief_title>Inflammatory Response Tissue Fibrosis/ Lymphatico-venous Bypass</brief_title>
	<detailed_description>If choose take part study , 1 small piece tissue ( size pencil eraser ) collect arm lymphedema another small piece tissue collect unaffected arm . A total 4 sample collect excisional biopsy ( 2 sample surgery 2 sample 6 month surgery ) . To collect excisional biopsy , area skin numb anesthetic small cut make remove part affected tissue . Blood ( 5 teaspoon time ) also draw surgery 1 blood sample 6 month surgery . If possible , blood sample collect already schedule blood draw avoid additional needle stick . The tissue blood sample use test evaluate level tissue inflammation check build-up excess tissue . Length Study : After tissue blood sample collect , participation study . This investigational study . Up 30 patient take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Genital Neoplasms , Female</mesh_term>
	<mesh_term>Urogenital Neoplasms</mesh_term>
	<criteria>1 . Patients undergo lymphaticovenular bypass lymphedema . 2 . History axillary lymph node dissection , sentinel lymph node biopsy dissection . 3 . A minimum three ( 3 ) month postop surgical intervention . 4 . A minimum six ( 6 ) month last dose chemotherapy . 5 . Patients unilateral lymphedema . 1 . Active systemic infection allergic reaction . 2 . Active parasitic infection . 3 . History primary ( congenital ) lymphedema . 4 . Metastatic cancer . 5 . History autoimmune disorder include lupus , rheumatoid arthritis , vasculitis , systemic sclerosis . 6 . History fibroproliferative disorder include cirrhosis , pulmonary fibrosis , kidney fibrosis , systemic sclerosis , scleroderma . 7 . Current treatment steroid . 8 . Concurrent secondary systemic cancer exclusive cutaneous malignancy . 9 . Treatment myelosuppressive stimulatory drug within six ( 6 ) month enrollment . 10 . History bone marrow transplantation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Breast cancer</keyword>
	<keyword>Genitourinary cancer</keyword>
	<keyword>Gynecological cancer</keyword>
	<keyword>Malignant Female Reproductive System Neoplasm</keyword>
	<keyword>Melanoma</keyword>
	<keyword>Sarcoma</keyword>
	<keyword>Inflammatory Response</keyword>
	<keyword>Inflammatory protein</keyword>
	<keyword>Tissue Fibrosis</keyword>
	<keyword>Lymphatico-venous Bypass Surgery</keyword>
	<keyword>Punch biopsy</keyword>
	<keyword>Lab collection</keyword>
	<keyword>Th2 immune phenotype</keyword>
	<keyword>Lymphedema</keyword>
</DOC>